Antonio Di Stefano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3852369/publications.pdf

Version: 2024-02-01

111 3,058
papers citations h-

32 48
h-index g-index

111 111 all docs citations

111 times ranked 4208 citing authors

#	Article	IF	CITATIONS
1	Synthesis and Biological Evaluation of Novel Cinnamic Acid-Based Antimicrobials. Pharmaceuticals, 2022, 15, 228.	1.7	12
2	Wound-Healing Promotion and Anti-Inflammatory Properties of Carvacrol Prodrugs/Hyaluronic Acid Formulations. Pharmaceutics, 2022, 14, 1468.	2.0	3
3	Glycyl-L-Prolyl-L-Glutamate Pseudotripeptides for Treatment of Alzheimer's Disease. Biomolecules, 2021, 11, 126.	1.8	8
4	Evaluation of In Vitro Capsaicin Release and Antimicrobial Properties of Topical Pharmaceutical Formulation. Biomolecules, 2021, 11, 432.	1.8	22
5	Antifungal Activity of Novel Formulations Based on Terpenoid Prodrugs against C. albicans in a Mouse Model. Pharmaceutics, 2021, 13, 633.	2.0	12
6	Potential Anticancer Effect of Carvacrol Codrugs on Human Glioblastoma Cells. Current Drug Delivery, 2021, 18, 350-356.	0.8	7
7	In Vitro Wound-Healing Properties of Water-Soluble Terpenoids Loaded on Halloysite Clay. Pharmaceutics, 2021, 13, 1117.	2.0	9
8	Anticancer effects of novel NSAIDs derivatives on cultured human glioblastoma cells. Zeitschrift Fur Naturforschung - Section C Journal of Biosciences, 2021, 76, 329-335.	0.6	4
9	Advances in Parkinson's Disease Drugs. Biomolecules, 2021, 11, 1640.	1.8	6
10	Novel anti-Alzheimer phenol-lipoyl hybrids: Synthesis, physico-chemical characterization, and biological evaluation. European Journal of Medicinal Chemistry, 2020, 186, 111880.	2.6	16
11	A Novel Prodrug of a nNOS Inhibitor with Improved Pharmacokinetic Potential. ChemMedChem, 2020, 15, 2157-2163.	1.6	4
12	Histidyl-Proline Diketopiperazine Isomers as Multipotent Anti-Alzheimer Drug Candidates. Biomolecules, 2020, 10, 737.	1.8	23
13	Nano-delivery systems based on carvacrol prodrugs and fibrous clays. Journal of Drug Delivery Science and Technology, 2020, 58, 101815.	1.4	7
14	Nonpharmacological treatment options for Alzheimer's disease: from animal testing to clinical studies. Turkish Journal of Zoology, 2020, 44, 81-89.	0.4	5
15	Neuroprotective effects of boron nitride nanoparticles in the experimental Parkinson's disease model against MPP+ induced apoptosis. Metabolic Brain Disease, 2020, 35, 947-957.	1.4	28
16	Carvacrol Prodrugs with Antimicrobial Activity Loaded on Clay Nanocomposites. Materials, 2020, 13, 1793.	1.3	9
17	Viscoelastic behaviour of hyaluronic acid formulations containing carvacrol prodrugs with antibacterial properties. International Journal of Pharmaceutics, 2020, 582, 119306.	2.6	8
18	Role of Dietary Supplements in the Management of Parkinson's Disease. Biomolecules, 2019, 9, 271.	1.8	51

#	Article	IF	Citations
19	Positive effect of an electrolyzed reduced water on gut permeability, fecal microbiota and liver in an animal model of Parkinson's disease. PLoS ONE, 2019, 14, e0223238.	1.1	24
20	Modulation of Apoptotic Cell Death and Neuroprotective Effects of Glutathioneâ€"L-Dopa Codrug Against H2O2-Induced Cellular Toxicity. Antioxidants, 2019, 8, 319.	2.2	6
21	Dysregulation in the Brain Protein Profile of Zebrafish Lacking the Parkinson's Disease-Related Protein DJ-1. Molecular Neurobiology, 2019, 56, 8306-8322.	1.9	26
22	Synthesis and Biological Evaluation of Novel Selenyl and Sulfur-l-Dopa Derivatives as Potential Anti-Parkinson's Disease Agents. Biomolecules, 2019, 9, 239.	1.8	8
23	Carvacrol prodrugs as novel antimicrobial agents. European Journal of Medicinal Chemistry, 2019, 178, 515-529.	2.6	45
24	Graphene Oxide increases mammalian spermatozoa fertilizing ability by extracting cholesterol from their membranes and promoting capacitation. Scientific Reports, 2019, 9, 8155.	1.6	13
25	Epigenetic Memory of Early-Life Parental Perturbation: Dopamine Decrease and DNA Methylation Changes in Offspring. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-11.	1.9	17
26	RNAIII Inhibiting Peptide (RIP) and Derivatives as Potential Tools for the Treatment of S. aureus Biofilm Infections. Current Topics in Medicinal Chemistry, 2019, 18, 2068-2079.	1.0	20
27	Synthesis and biological evaluation of novel analogues of Gly-I-Pro-I-Glu (GPE) as neuroprotective agents. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 194-198.	1.0	10
28	Carvacrol and its derivatives as antibacterial agents. Phytochemistry Reviews, 2018, 17, 903-921.	3.1	115
29	Advances in prodrug design for Parkinson's disease. Expert Opinion on Drug Discovery, 2018, 13, 295-305.	2.5	13
30	Natural oxyprenylated coumarins are modulators of melanogenesis. European Journal of Medicinal Chemistry, 2018, 152, 274-282.	2.6	22
31	Chelating and antioxidant properties of l-Dopa containing tetrapeptide for the treatment of neurodegenerative diseases. Neuropeptides, 2018, 71, 11-20.	0.9	9
32	Synthesis, Characterization and Evaluation of Gemfibrozil-Stilbene Hybrid as Antioxidant Agent. Letters in Drug Design and Discovery, 2018, 15, 1230-1238.	0.4	8
33	Nanoencapsulation strategies for the delivery of novel bifunctional antioxidant/ $if1$ selective ligands. Colloids and Surfaces B: Biointerfaces, 2017, 155, 238-247.	2.5	16
34	L-dopa co-drugs in nanostructured lipid carriers: A comparative study. Materials Science and Engineering C, 2017, 72, 168-176.	3.8	20
35	(R)-α-Lipoyl-Gly-l-Pro-l-Glu dimethyl ester as dual acting agent for the treatment of Alzheimer's disease. Neuropeptides, 2017, 66, 52-58.	0.9	21
36	Memantine-derived drugs as potential antitumor agents for the treatment of glioblastoma. European Journal of Pharmaceutical Sciences, 2017, 109, 402-411.	1.9	31

#	Article	IF	Citations
37	Editorial: Neurodegenerative Disorders: Synthesis, Drug Delivery Strategies and Biological Evaluation of New Therapeutic Agents. Central Nervous System Agents in Medicinal Chemistry, 2017, 17, 89.	0.5	1
38	Synthesis and Antioxidant Properties of Novel Memantine Derivatives. Central Nervous System Agents in Medicinal Chemistry, 2017, 17, 123-128.	0.5	7
39	Effect of MRJF4 on C6 Glioma Cells Proliferation and Migration. Central Nervous System Agents in Medicinal Chemistry, 2017, 17, 129-134.	0.5	6
40	Health risk assessments of lithium titanate nanoparticles in rat liver cell model for its safe applications in nanopharmacology and nanomedicine. Cytotechnology, 2016, 68, 291-302.	0.7	9
41	Novel NSAID-Derived Drugs for the Potential Treatment of Alzheimer's Disease. International Journal of Molecular Sciences, 2016, 17, 1035.	1.8	26
42	Efficacy of the Quorum Sensing Inhibitor FS10 Alone and in Combination with Tigecycline in an Animal Model of Staphylococcal Infected Wound. PLoS ONE, 2016, 11, e0151956.	1.1	45
43	New bifunctional antioxidant/ $lf1$ agonist ligands: Preliminary chemico-physical and biological evaluation. Bioorganic and Medicinal Chemistry, 2016, 24, 3149-3156.	1.4	7
44	Solid lipid nanoparticles as a drug delivery system for the treatment of neurodegenerative diseases. Expert Opinion on Drug Delivery, 2016, 13, 1121-1131.	2.4	99
45	Preparation and characterization of polymeric micelles loaded with a potential anticancer prodrug. Journal of Drug Delivery Science and Technology, 2016, 35, 24-29.	1.4	5
46	Singleâ€Walled Carbon Nanotubes in Highly Viscous Media: A Comparison between the Dispersive Agents [BMIM][BF ₄], L121, and Triton Xâ€100. Chemistry - A European Journal, 2016, 22, 546-549.	1.7	13
47	Development of glycine-α-methyl-proline-containing tripeptides with neuroprotective properties. European Journal of Medicinal Chemistry, 2016, 108, 553-563.	2.6	13
48	Nanotherapeutics for anti-inflammatory delivery. Journal of Drug Delivery Science and Technology, 2016, 32, 174-191.	1.4	21
49	The investigation of cytogenetic and oxidative effects of diffractaic acid on human lymphocyte cultures. Brazilian Archives of Biology and Technology, 2015, 58, 75-81.	0.5	6
50	Carvacrol Codrugs: A New Approach in the Antimicrobial Plan. PLoS ONE, 2015, 10, e0120937.	1.1	50
51	Hepatic effects of yttrium oxide nanoflowers: <i>in vitro</i> risk evaluation. Toxicological and Environmental Chemistry, 2015, 97, 599-608.	0.6	7
52	Solid lipid nanoparticles loaded with lipoyl–memantine codrug: Preparation and characterization. International Journal of Pharmaceutics, 2015, 485, 183-191.	2.6	60
53	HPLC–FLD and spectrofluorometer apparatus: How to best detect fluorescent probe-loaded niosomes in biological samples. Colloids and Surfaces B: Biointerfaces, 2015, 135, 575-580.	2.5	12
54	Lipid nanocarriers containing a levodopa prodrug with potential antiparkinsonian activity. Materials Science and Engineering C, 2015, 48, 294-300.	3.8	11

#	Article	IF	CITATIONS
55	Protective effects of cyclosativene on H2O2-induced injury in cultured rat primary cerebral cortex cells. Cytotechnology, 2015, 67, 299-309.	0.7	27
56	Haloperidol metabolite II prodrug: Asymmetric synthesis and biological evaluation on rat C6 glioma cells. European Journal of Medicinal Chemistry, 2015, 90, 1-9.	2.6	35
57	Synthesis of a Novel Cyclic Prodrug of $\langle i \rangle S \langle i \rangle$ -Allyl-glutathione Able To Attenuate LPS-Induced ROS Production through the Inhibition of MAPK Pathways in U937 Cells. Molecular Pharmaceutics, 2015, 12, 66-74.	2.3	32
58	Evidence for a Dopamine Intrinsic Direct Role in the Regulation of the Ovary Reproductive Function: In Vitro Study on Rabbit Corpora Lutea. PLoS ONE, 2014, 9, e104797.	1.1	14
59	The Risk Evaluation of Tungsten Oxide Nanoparticles in Cultured Rat Liver Cells for Its Safe Applications in Nanotechnology. Brazilian Archives of Biology and Technology, 2014, 57, 532-541.	0.5	24
60	Neuroprotective Effects of Farnesene Against Hydrogen Peroxide-Induced Neurotoxicity In vitro. Cellular and Molecular Neurobiology, 2014, 34, 101-111.	1.7	31
61	Evaluation of cytotoxic, oxidative stress and genotoxic responses of hydroxyapatite nanoparticles on human blood cells. Journal of Applied Toxicology, 2014, 34, 373-379.	1.4	53
62	Temporal expression of <i>agrB </i> , <i>cidA </i> , and <i>alsS </i> in the early development of <i>Staphylococcus aureus </i> UAMS-1 biofilm formation and the structural role of extracellular DNA and carbohydrates. Pathogens and Disease, 2014, 70, 414-422.	0.8	38
63	Effect of $17\hat{1}^2$ -estradiol on striatal dopaminergic transmission induced by permethrin in early childhood rats. Chemosphere, 2014, 112, 496-502.	4.2	9
64	Memantine-sulfur containing antioxidant conjugates as potential prodrugs to improve the treatment of Alzheimer's disease. European Journal of Pharmaceutical Sciences, 2013, 49, 187-198.	1.9	58
65	Effects of early life permethrin exposure on spatial working memory and on monoamine levels in different brain areas of pre-senescent rats. Toxicology, 2013, 303, 162-168.	2.0	74
66	A Glutathione Derivative with Chelating and in vitro Neuroprotective Activities: Synthesis, Physicochemical Properties, and Biological Evaluation. ChemMedChem, 2013, 8, 1818-1829.	1.6	32
67	New Flurbiprofen Derivatives: Synthesis, Membrane Affinity and Evaluation of in Vitro Effect on \hat{l}^2 -Amyloid Levels. Molecules, 2013, 18, 10747-10767.	1.7	21
68	Surfactant Hydrogels for the Dispersion of Carbonâ€Nanotubeâ€Based Catalysts. Chemistry - A European Journal, 2013, 19, 16415-16423.	1.7	27
69	Ibuprofen and Lipoic Acid Conjugate Neuroprotective Activity Is Mediated by Ngb/Akt Intracellular Signaling Pathway in Alzheimer's Disease Rat Model. Gerontology, 2013, 59, 250-260.	1.4	25
70	Modulation of Monoaminergic Transporters by Choline-Containing Phospholipids in Rat Brain. CNS and Neurological Disorders - Drug Targets, 2013, 12, 94-103.	0.8	10
71	Designing prodrugs for the treatment of Parkinson's disease. Expert Opinion on Drug Discovery, 2012, 7, 385-406.	2.5	27
72	(<i>R</i>)â€Î±â€Lipoylâ€Glycylâ€ <scp>L</scp> â€Prolylâ€ <scp>L</scp> â€Glutamyl Dimethyl Ester Codrug as a Multifunctional Agent with Potential Neuroprotective Activities. ChemMedChem, 2012, 7, 2021-2029.	1.6	39

#	Article	IF	CITATIONS
73	CNS delivery of l-dopa by a new hybrid glutathione–methionine peptidomimetic prodrug. Amino Acids, 2012, 42, 261-269.	1.2	20
74	Synthesis of Novel 4-Aryl-1,2,3,4-tetrahydroisoquinolines as Probes for Dopamine Receptor Ligands. Medicinal Chemistry, 2012, 8, 699-704.	0.7	0
75	Effect of choline-containing phospholipids on brain cholinergic transporters in the rat. Journal of the Neurological Sciences, 2011, 302, 49-57.	0.3	40
76	Drug delivery strategies for Alzheimer's disease treatment. Expert Opinion on Drug Delivery, 2011, 8, 581-603.	2.4	79
77	Potential Antibacterial Activity of Carvacrol-Loaded Poly(DL-lactide-co-glycolide) (PLGA) Nanoparticles against Microbial Biofilm. International Journal of Molecular Sciences, 2011, 12, 5039-5051.	1.8	139
78	L-Dopa Prodrugs: An Overview of Trends for Improving Parkinsons Disease Treatment. Current Pharmaceutical Design, 2011, 17, 3482-3493.	0.9	36
79	NOS-mediated morphological and molecular modifications in rats infused with $A\hat{l}^2$ (1-40), as a model of Alzheimer's disease, in response to a new lipophilic molecular combination codrug-1. Experimental Gerontology, 2011, 46, 273-281.	1.2	8
80	Ibuprofen and Glutathione Conjugate as a Potential Therapeutic Agent for Treating Alzheimer's Disease. Archiv Der Pharmazie, 2011, 344, 139-148.	2.1	43
81	Ibuprofen and Lipoic Acid Diamides as Potential Codrugs with Neuroprotective Activity. Archiv Der Pharmazie, 2010, 343, 133-142.	2.1	45
82	Design, synthesis, and preliminary pharmacological evaluation of new imidazolinones as l-DOPA prodrugs. Bioorganic and Medicinal Chemistry, 2010, 18, 1834-1843.	1.4	27
83	Novel imidazoline compounds as partial or full agonists of D2-like dopamine receptors inspired by I2-imidazoline binding sites ligand 2-BFI. Bioorganic and Medicinal Chemistry, 2010, 18, 7085-7091.	1.4	12
84	Prodrug Approach for Increasing Cellular Glutathione Levels. Molecules, 2010, 15, 1242-1264.	1.7	96
85	Viscoelastic properties of <i>Staphylococcus aureus</i> and <i>Staphylococcus epidermidis</i> monoâ€microbial biofilms. Microbial Biotechnology, 2009, 2, 634-641.	2.0	45
86	Stimulation of human macrophages (THP-1) using Toll-like receptor-2 (TLR-2) agonist decorated nanocarriers. Journal of Drug Targeting, 2009, 17, 662-670.	2.1	33
87	Codrugs Linking <scp>l</scp> -Dopa and Sulfur-Containing Antioxidants: New Pharmacological Tools against Parkinson's Disease. Journal of Medicinal Chemistry, 2009, 52, 559-563.	2.9	55
88	New drug delivery strategies for improved Parkinson's disease therapy. Expert Opinion on Drug Delivery, 2009, 6, 389-404.	2.4	53
89	New Lâ€Dopa Codrugs as Potential Antiparkinson Agents. Archiv Der Pharmazie, 2008, 341, 412-417.	2.1	28
90	Characterization of alkanoyl-10-O-minocyclines in micellar dispersions as potential agents for treatment of human neurodegenerative disorders. European Journal of Pharmaceutical Sciences, 2008, 34, 118-128.	1.9	12

#	Article	lF	CITATIONS
91	Antiparkinson Prodrugs. Molecules, 2008, 13, 46-68.	1.7	44
92	Synthesis and Study ofl-Dopaâ^'Glutathione Codrugs as New Anti-Parkinson Agents with Free Radical Scavenging Properties. Journal of Medicinal Chemistry, 2007, 50, 2506-2515.	2.9	63
93	Dopaminergic system modulation, behavioral changes, and oxidative stress after neonatal administration of pyrethroids. Toxicology, 2007, 229, 194-205.	2.0	153
94	L-Dopaâ^' and Dopamineâ^'(R)-α-Lipoic Acid Conjugates as Multifunctional Codrugs with Antioxidant Properties. Journal of Medicinal Chemistry, 2006, 49, 1486-1493.	2.9	72
95	Maleic- and fumaric-diamides of (O,O-diacetyl)-L-Dopa-methylester as anti-Parkinson prodrugs in liposomal formulation. Journal of Drug Targeting, 2006, 14, 652-661.	2.1	32
96	Preparation and Pharmacological Characterization oftrans-2-Amino-5(6)-fluoro-6(5)-hydroxy-1-phenyl-2,3-dihydro-1H-indenes as D2-like Dopamine Receptor Agonists. Journal of Medicinal Chemistry, 2005, 48, 2646-2654.	2.9	43
97	Evaluation of rat striatal l-dopa and DA concentration after intraperitoneal administration of l-dopa prodrugs in liposomal formulations. Journal of Controlled Release, 2004, 99, 293-300.	4.8	51
98	Transition state isosteres of thel³-glutamyl peptide bond hydrolysis: synthesis and characterization of thel˚[CH2NH] pseudopeptide analogue of glutathione. Journal of Peptide Science, 2004, 10, 109-114.	0.8	5
99	Choline pivaloyl esters improve in rats cognitive and memory performances impaired by scopolamine treatment or lesions of the nucleus basalis of Meynert. Neuroscience Letters, 2004, 356, 199-202.	1.0	23
100	Synthesis and biological evaluation of GABA derivatives able to cross the blood–Brain barrier in rats. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 3765-3769.	1.0	9
101	Synthesis and biological evaluation of the disulfide form of the glutathione analogue \hat{I}^3 -(l-glutamyl)-l-cysteinyl-l-aspartyl-l-cysteine. Bioorganic Chemistry, 2003, 31, 109-121.	2.0	3
102	Proline–Glutamate Chimeras in Isopeptides. Synthesis and Biological Evaluation of Conformationally Restricted Glutathione Analogues. Bioorganic and Medicinal Chemistry, 2003, 11, 1677-1683.	1.4	14
103	Synthesis and preliminary pharmacological evaluation of trans-2-amino-5(6)-chloro-6(5)-hydroxy-1-phenyl-2,3-dihydro-1H-indenes as dopamine receptor ligands. Il Farmaco, 2002, 57, 303-313.	0.9	5
104	Dimeric l-Dopa Derivatives as Potential Prodrugs. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 1085-1088.	1.0	32
105	Synthesis and preliminary pharmacological evaluation of 5-Hydroxy- and 5,6-dihydroxy-1,2,3,7,12,12a-hexahydrobenzo[5,6]cyclohepta[1,2,3-ij]isoquinoline derivatives as dopamine receptor ligands. Bioorganic and Medicinal Chemistry, 2001, 9, 1447-1458.	1.4	4
106	Synthesis of l-(+)-3-(3-hydroxy-4-pivaloyloxybenzyl)-2,5-diketomorpholine as potential prodrug of l-dopa. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 1385-1388.	1.0	36
107	Binding and Preliminary Evaluation of 5-Hydroxy- and 10-Hydroxy-2,3,12,12a-tetrahydro-1H-[1]benzoxepino[2,3,4-ij]isoquinolines as Dopamine Receptor Ligands. Journal of Medicinal Chemistry, 2000, 43, 599-608.	2.9	19
108	$\hat{\Gamma}$ (SO2NH) transition state isosteres of peptides. Synthesis and bioactivity of sulfonamido pseudopeptides related to carnosine. Il Farmaco, 1999, 54, 673-677.	0.9	14

ANTONIO DI STEFANO

#	Article	IF	CITATIONS
109	Simplified analogues of ritanserin and their affinity at 5-HT2A, 5-HT2B and 5-HT2C serotonin receptors. European Journal of Medicinal Chemistry, 1998, 33, 705-713.	2.6	3
110	Synthesis, Resolution, and Preliminary Evaluation oftrans-2-Amino-6(5)-hydroxy-1-phenyl-2,3-dihydro-1H-indenes and Related Derivatives as Dopamine Receptors Ligands. Journal of Medicinal Chemistry, 1996, 39, 4238-4246.	2.9	13
111	Synthesis and pharmacological characterization of 2-(4-chloro-3-hydroxyphenyl)ethylamine and N,N-dialkyl derivatives as dopamine receptor ligands. Journal of Medicinal Chemistry, 1992, 35, 4408-4414.	2.9	17